Clinical Report: Bone Health in Parathyroid Disorders and Therapeutic Insights
Overview
Parathyroid hormone (PTH) disorders significantly affect bone metabolism, with hyperparathyroidism causing increased bone resorption and hypoparathyroidism leading to low bone turnover and altered microarchitecture. Surgical and medical treatments, including parathyroidectomy, calcimimetics, antiresorptives, and recombinant PTH, play crucial roles in managing skeletal complications.
Background
PTH is essential for calcium and phosphate homeostasis and bone remodeling. Hyperparathyroidism, characterized by excessive PTH, increases bone turnover favoring resorption, leading to bone loss and fractures. Hypoparathyroidism results in PTH deficiency, causing low bone turnover and increased bone mineral density but impaired bone quality. Advances in diagnostic accessibility have enabled earlier detection of parathyroid disorders, often before severe skeletal manifestations develop.
Data Highlights
Primary hyperparathyroidism (PHPT) is the most common parathyroid disorder, typically caused by parathyroid adenomas. Secondary hyperparathyroidism (SHPT) arises from hypocalcemia-driven PTH overproduction, often due to calcium homeostasis defects. Hypoparathyroidism usually results from neck surgery complications and is characterized by low or absent PTH levels with hypocalcemia. Treatments include parathyroidectomy, calcimimetics, antiresorptive agents, calcium, active vitamin D, and recombinant human PTH (teriparatide).
Key Findings
Hyperparathyroidism leads to increased bone turnover and resorption, causing decreased bone mineral density and skeletal fragility.
Primary hyperparathyroidism is commonly due to autonomous PTH secretion from adenomas, with classic severe bone disease now rare.
Secondary hyperparathyroidism results from hypocalcemia-induced PTH overproduction, not autonomous gland activity.
Hypoparathyroidism causes low bone turnover and increased bone mineral density but impaired bone microarchitecture and strength.
Parathyroidectomy is the definitive treatment for hyperparathyroidism, promoting skeletal recovery.
Medical therapies such as calcimimetics and antiresorptives offer alternatives when surgery is not feasible or unsuccessful.
Recombinant human PTH is effective in hypoparathyroidism refractory to conventional calcium and vitamin D therapy.
Clinical Implications
Early diagnosis of parathyroid disorders allows intervention before severe skeletal damage occurs. Parathyroidectomy remains the gold standard for hyperparathyroidism, but medical therapies provide important options for non-surgical candidates. In hypoparathyroidism, recombinant PTH can restore bone turnover and mineral homeostasis in refractory cases, complementing standard calcium and vitamin D supplementation.
Conclusion
Parathyroid disorders profoundly impact bone health through distinct mechanisms of altered PTH secretion. Understanding these effects and available treatments enables tailored management to mitigate skeletal complications and improve patient outcomes.
References
Reexamining Bone Health in Parathyroid Disorders: Insights from Epidemiological Studies, Surgical Interventions, and Novel Therapeutics
